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Odette R Gibson1*, Leonie Segal1 and Robyn A McDermott2Abstract
Background: To develop an instrument that predicts diabetes-related vascular disease severity using routinely
collected data on Australian Aboriginal and Torres Strait Islander adults with type 2 diabetes, in the absence of
diabetes duration.
Methods: A complex diabetes severity classification system was simplified and adapted for use with an Australian
Aboriginal and Torres Strait Islander adult population with type 2 diabetes in north Queensland. Detailed vascular
health risks and morbidities were mapped to routinely collected measures. Individual–level health screening,
hospital separation and mortality data were linked and used to plot mean monthly in-patient hospital cost and
percent mortality by disease severity as defined by the newly developed instrument, to test construct validity.
Results: The revised instrument consists of four combined diabetes-related microvascular and macrovascular stages
that range from least severe (stage 1) to severe irreversible vascular impairment (stage 4). When applied to data of
an Aboriginal and Torres Strait Islander Australian population the instrument showed good construct validity,
predicting higher hospital cost and mortality as vascular disease severity increased.
Conclusions: This instrument discriminates between levels of diabetes-related vascular disease severity, displays
good construct validity by predicting increased hospital cost and mortality with worsening severity and can be
populated with routinely collected data. It may assist with future health service research and its use could be
extended to practice settings for health care planning for diabetes management programs and monitoring vascular
disease progression.
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Type 2 diabetes is one of the most common non-
communicable diseases in the world and results in sub-
stantial morbidity and premature mortality [1]. The inci-
dence and prevalence of diabetes is rising in developed
and developing countries, the age of onset is becoming
younger in adults and prevalence of type 2 diabetes in
children is increasing [2]. Diabetes is a contributing* Correspondence: odette.gibson@unisa.edu.au
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reproduction in any medium, provided the orfactor to cardiovascular disease [3] and a leading cause
of end stage renal failure [4]. These complications are a
great burden to patients and society [5], incur high
health service use and contribute excessively to the cost
of health care [6].
In evaluating the impact of primary health care resour-
cing on hospital use and mortality in a high risk popula-
tion of Australian Indigenous adults with type 2 diabetes
it was necessary to control for the potential confounding
of diabetes-related health status. Given a relatively small
sample cohort (n = 379) and no reliable estimate of dia-
betes duration, a simple measure of diabetes-related
health status was sought. We adapted a complex vascularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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coordinated care trial to our study population.
A Trial of Integrated Care for persons with Diabetes
commenced in 1996 in three pilot sites across Australia,
including the mid-north coast New South Wales (NSW).
An objective of the trial was to document the costs of
management over two years. Annual health care cost per
person, by disease severity was estimated [7]. An expert
clinical group informed the development of a vascular
staging system to classify diabetes according to clinical
severity. The resulting severity classification system con-
sisted of four microvascular and four macrovascular dis-
ease stages based on 44 detailed comorbidities [7]. The
four microvascular stages followed diabetes-related vas-
cular disease progression from mild to severe irreversible
microvascular impairment and likewise the four macro-
vascular stages. It had a dual classification staging sys-
tem that assigned each individual to one of 16 possible
joint micro/macrovascular stages (micro 1–4; macro 1–
4). The most severe microvascular and macrovascular
stage met determined an individuals’ vascular score.
Available data on trial participants sourced from the trial
developed clinical/audit management form, hospital in-
patient and outpatient services, general practice services
and pharmaceutical records held by the Health Insur-
ance Commission were used to populate the instrument.
Results of the economic analysis showed an increase in
mean annual cost of inpatient services at every disease
stage, across both microvascular and macrovascular
stages, for the NSW population with diabetes.
Our objective was to revise the NSW diabetes classifi-
cation system to arrive at a simple diabetes vascular se-
verity staging instrument that used only data collected
routinely in health practice settings, plus hospitalisation
data. This paper describes the revisions made to the
NSW instrument, the method used to match health
screening data with hospital separation and death data,
and the performance of the new instrument mapped
against hospital cost and mortality when applied to our
study population.Methods
Defining microvascular and macrovascular disease stages
A microvascular complication was defined as early signs
of diabetic nephropathy or evidence of established dia-
betic nephropathy or retinopathy. Macrovascular com-
plications captured clinical risks of acquiring, or
evidence of, cardiovascular disease, peripheral vascular
disease or cerebrovascular vascular disease. Generally an
early sign of a vascular complication was determined by
results of a health check (abnormal lipid profile, high
blood pressure), and evidence of a vascular complication
was determined by being hospitalised for the condition.Revisions to the existing vascular staging instrument
Microvascular and macrovascular detailed classification
items were combined within their broad vascular stages.
Vascular stage 1 is defined by absence of microvascular
disease or macrovascular risk factors (but allows for the
presence of lifestyle risk factors, like obesity and smok-
ing, which while risk factors for diabetes are not per se
evidence of disease progression). Screen-detected micro-
vascular comorbidities and risk factors for macrovascu-
lar disease were combined and form vascular stage 2.
Likewise moderate microvascular and macrovascular
comorbidities were combined to create one vascular
stage (stage 3) and late-stage micro and macro vascular
comorbidities were combined to form vascular stage 4.
Albumin/creatinine ratio (ACR) was chosen as a meas-
ure of the early sign of diabetic nephropathy. Proteinuria
in the original instrument was replaced by macroalbumi-
nuria and microalbuminuria (measured by urinary ACR)
for the ability to differentiate between levels of kidney
function [8]. Elevated cholesterol >5.5 mmol/L was
replaced by elevated triglycerides >1.5 mmol/L due to evi-
dence that dyslipidemia in the Australian Aboriginal and
Torres Strait Islander population is characterised by a lipid
profile of elevated triglycerides levels >1.5 mmol/L and
reduced high density lipoprotein (HDL) cholesterol
<1.0 mmol/L rather than elevated total cholesterol [9].
Detailed classification items not routinely collected for
annual health checks or hospital separation were
excluded. Items excluded were stroke without residual
deficit, background retinopathy on retinal examination,
abnormal peripheral sensation, areas of dried skin on
the feet or distinct foot callus present on examination,
ankle reflexes absent and abnormal distal foot impulse
and serum creatinine. Self-reported smoking was
excluded from the staging because it is not evidence of
vascular disease. Smoking would be included as a dis-
tinct variable in our statistical models. Table 1 details in-
clusion criteria for the new instrument with 4 stages.
Mapping objective measures to detailed classification
items
Current reference ranges for screen-detected measures
were mapped to relevant detailed classification items
and referenced. Australian Refined Diagnosis Related
Group Version 5.0 (AR-DRGv5.0) codes were mapped to
the remaining detailed classification items by one of the
authors (RM).
Data sources
A cross sectional population health screen known as the
Well Persons Health Check (WPHC) was conducted in 26
communities in north Queensland Australia. Ethics ap-
proval was granted by Cairns Base hospital, Queensland
Health. A detailed WPHC study protocol is published
Table 1 Revised type 2 diabetes vascular staging
instrument with detailed classification items and their
measures
Vascular stage & broad classification of stages
Detailed classification item Measures (Australian Refined
Diagnosis Related Group code
version 5.0* or clinical reference
range)
1 Diagnosis of type 2 diabetes Doctor diagnosis confirmed by a
medical chart audit or a fasting
blood glucose level≥ 7 mmol/L†
or 2-hour glucose tolerance test
result of blood glucose
level≥ 11.1 mmol/L †[10] or a
hospital admission for diabetes
With no evidence of microvascular or macrovascular risk factors (but
may be obese or report current tobacco smoking)
Albumin creatinine ratio (ACR)
within normal range
ACR of 0–2.5 mg/mmol for men
and 0–3.5 mg/mmol for women{
Normal high density lipoprotein
cholesterol (HDLC)
> 1.0 mmol/L}
Normal triglycerides < 1.5 mmol/L}
Not hypertensive Not hospitalised for hypertension
(DRG code F67A or F67B), or
blood pressure< 140/90 mmHg ||
No evidence of retinopathy Not hospitalised for retinal
procedures and vascular disorders of
the eye (DRG code C03Z or C16Z)
Peripheral sensation normal and
no evidence of claudication
Not hospitalised for DRG code
F65A or F65B
No cardiac disease Not hospitalised for DRG code
A05Z, F12Z, F14A, F14B, F62Z,
F62B, F70A, F70B, F62A, F14C,
F15Z, F16Z, F17Z, F18Z, F19Z,
F10Z, F41A, F41B, F60A, F60B or
F60C
2 Screen-detected microvascular comorbidities and/or risk factors for
macrovascular disease
Microalbuminuria ACR 2.6–25 mg/mmol for men
and 3.6-35 mg/mmol for women{
Reduced HDLC ≤ 1.0 mmol/L}
Elevated triglycerides ≥ 1.5 mmol/L}
Hypertension Hospitalised for DRG code F67A
or F67B, or systolic blood
pressure≥ 140 mm Hg and/or a
diastolic blood pressure≥ 90 mm
Hg||
3 Moderate microvascular and/or macrovascular comorbidities
Macroalbuminuria ACR> 25 mmol/L for men
and> 35 mmol/L for women{
History of coronary artery bypass
graft or angioplasty
F05A, F05B, F06A, F06B
History of carotid artery disease F66A, F66B
History of or hospitalised for
angina
F72A, F72B
History of claudication or
peripheral vascular disease
F65A, F65B
Table 1 Revised type 2 diabetes vascular staging
instrument with detailed classification items and their
measures (Continued)
4 Late-stage diabetes macrovascular and/or microvascular comorbidities
Amputation of lower limb F11A, F11B, F13Z, I07Z, I14Z
Present or history of gangrene of
the lower limb
J13A, J13B, J64A, J64B
History of stroke with residual
deficit
B69A, B69B, B70A, B70B, B70C,
B70D
History of or hospitalised for
cardiac failure
A05Z, F12Z, F14A, F14B, F62A,
F62B, F70A, F70B
History of myocardial infarction F14C, F15Z, F16Z, F17Z, F18Z,
F19Z, F10Z, F41A, F41B, F60A,
F60B, F60C
Proliferative retinopathy and
both eyes: only able to perceive
light or hand movement or
count fingers, or unable to
perceive light
C03Z, C16Z
Present or history of
osteomyelitis or ulcer of the foot
or charcot joint
I64A, I64B
Bacterial soft tissue infection of
the foot
J12A, J12B, J12C,




History of end-stage renal failure L60A, L60B, L60C
History of dialysis L61Z
History of renal transplant A09A, A09B
Sources:
* Department of Health and Aging: Public Sector - Estimated Round 9 (2004–
05) AR_DRG 5.0 Cost Report.
[http://www.health.gov.au/internet/main/publishing.nsf/Content/
88F4E78E15620A80CA2571CB0004DDAA/$File/_R9CWQLDEst.pdf]
{Diabetes Australia’s Health Care and Education Committee and RACGP's
National Standing Committee for Quality Care in 2010: Diabetes management
in general practice. [http://www.racgp.org.au/Content/NavigationMenu/
ClinicalResources/RACGPGuidelines/Diabetesmanagement/
200910diabetesmanagementingeneralpractice.pdf]
|| National Blood Pressure Advisory Committee: Hypertension management
guide for doctors 2004. [http://www.sld.cu/galerias/pdf/servicios/hta/
hypertension_management_guide_australia_2004.pdf]
}National Heart Foundation of Australia and Cardiac Society of Australia and
New Zealand: Lipid management guidelines-summary paper. Medical J Aust
2001, 175: S57-S88.
†World Health Organization: Part 1: diagnosis and classification of diabetes
mellitus, in: definition, diagnosis and classification of diabetes mellitus and its
complications. [http://www.staff.ncl.ac.uk/philip.home/who_dmg.pdf]
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1998 for a period of one week in each community and
were completed in December 2000. People aged 13 years
and over volunteered to participate (n= 3507). Demog-
raphy, anthropometric and biochemical measures and
self-reported lifestyle behaviors were collected with the
primary purpose of early detection and intervention in re-
lation to chronic diseases. This study cohort is adults aged
15 years and over who participated in the WPHC study
with a medical diagnosis of type 2 diabetes (n= 379) prior
Table 2 Characteristics of the study cohort (N= 379)
Mean age (years) (SD) (range) 48 (12.5) (17 – 85)
Proportion female 58 %
Mean body mass index (kg/m2)* (n = 376)
(SD) (range)
32 (6.4) (16.2 – 52.4)
Waist circumference men <102 cm* 33 %
Waist circumference women <88 cm* 4 %
Fasting blood glucose level< 5.5 mmol/L† (n=373) 3.5 %
Blood pressure <140/90 mmHg{ (n = 378) 51.8 %
Macroalbuminuria† (n = 356) 34.5 %
Source: Well Persons Health Check, north Queensland, 1998 – 2000.
*National Health and Medical Research Council: Clinical practice guidelines for
the management of overweight and obesity in adults. [http://www.health.gov.
au/internet/main/publishing.nsf/Content/
7AF116AFD4E2EE3DCA256F190003B91D/$File/adults_contents.pdf]
†Diabetes Australia's Health Care and Education Committee, RACGP's National
Standing Committee for Quality Care in 2010: Diabetes management in
general practice. [http://www.racgp.org.au]
{National Blood Pressure Advisory Committee: Hypertension management
guide for doctors 2004. [http://www.sld.cu/galerias/pdf/servicios/hta/
hypertension_management_guide_australia_2004.pdf]
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and Dec 2000).
Hospital separation data on consenting WPHC partici-
pants from eight public hospitals for the period 25 May
1997 to 31 December 2005 were collected. These are the
major referral hospitals for the communities. Death data
were sought from the Queensland State Registrar Office
of Births, Deaths and Marriages [12].
Data linkage
Deterministic record linkage based on hospital unit rec-
ord numbers was used to match individual health screen
to hospital separation data and death data were matched
manually. A match protocol was developed. A random
sample technique was used to validate the match proto-
col, comparing the clinical and demographic features of
the health screening client record with those of the hos-
pital record. Information was also sourced from Royal
Flying Doctor Service evacuation notes, clinical diagno-
ses, or other notes to reach surety that the clients in the
health screen and the hospital record were the same per-
son. A potential match was considered false when the
potential match could not be confirmed within the pa-
tient hospital record.
Eight years of hospital separation data spanning across
3 diagnosis related group (DRG) versions (3.1 (1995–
1997) and 4.0 (1998–2001)) were mapped to A-R
DRGv5.0 (2002–2006) [13] with assistance from the
Classification Management and Statistics Section
Healthcare Services Information Branch, Acute Care
Division of the Australian Department of Health and
Aging using the DrGroup, Australian Refinement DRG
Grouper, PC Version 6.0 (Batch), Visasys Pty Ltd
Canberra.
Instrument application
The WPHC data were analysed to find patients with a
diagnosis of diabetes and each case identified was
assigned to one of the four vascular stages using the cri-
teria defined in Table 1. Assignment to vascular stage 1
requires the absence of microvascular complications and
macrovascular risk factors identified in stages 2 to 4. As-
signment to vascular stages 2, 3 or 4 occurs when one or
more detailed classification items within a stage is
present. Individuals are assigned to the highest vascular
stage they meet.
Analysis
The vascular disease severity score was mapped against
mean in-patient hospital cost and death to test how the
staging allocation performed. Hospital costs were
accrued for each individual from the date of assignment
of the vascular score (vascular date) to date of death or
31 December 2005. Hospital cost was defined by bedday adjusted DRG cost for each hospital admission (pa-
tient length of stay/mean DRG length of stay * DRG cost
weight * 2004/05 DRG dollar value - $2989) using 2004/
05 Queensland estimated hospital cost report [14]. To
arrive at the mean monthly hospital cost the sum of bed
day adjusted DRG costs for each individual was divided
by the number of months between their vascular date
and 31 December 2005 or date of death. Total in-patient
hospital cost of each individual within each stage was
summed and divided by the number of people in the
vascular stage. Mean monthly in-patient hospital costs
were presented by vascular stage and confidence inter-
vals were derived by bootstrapping. At each vascular
stage percent of persons who died was calculated. Con-
struct validity was assessed by testing for the expected
relationship between the new diabetes severity score and
hospitalisation and mortality. All analyses were per-
formed using Stata for Windows Version 10 (StataCorp,
1984–2007).
Results
Revisions to a complex vascular severity dual classification
system have resulted in a simplified instrument with four
stages. The instrument comprises vascular risks and con-
ditions that are derivable from routinely collected primary
health care and hospital data (Table 1). When applied the
instrument reports a single individual score of vascular
disease severity. Table 2 shows the study cohort character-
istics. In general, compared to non-Indigenous Australians
with diabetes, there are significant differences. The study
cohort is younger, more females than males have diabetes,
and a higher percentage has macroalbuminuria. Mean
BMI is similar, a higher percentage of the study cohort
have well controlled blood pressure (<140/90 mmHg) but
Figure 2 Mean monthly in-patient hospital cost per person by
vascular stage. Mean monthly in-patient hospital cost (04/05
Australian dollars*) by vascular stage after applying the simplified
vascular staging instrument using the public sector Queensland
estimated round 9 cost report 2004–05 and hospital admission data
from eight Queensland public hospitals (25 May 1997–31 Dec 2005)
on a cohort of Aboriginal and Torres Strait Islander adults with type
2 diabetes who participated in the Queensland Well Persons Health
Check (1998–2000). N = 379. Hospital cost is derived from the date
of assignment to their vascular stage to date of death or 31
December 2005.
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adults with diabetes [15]. During the 5 year follow-up
period 60 % of the study cohort was hospitalised and 12 %
percent became deceased. Diabetes duration was not
documented for two thirds of this study cohort and unre-
liable for the remaining one third.
Figure 1 shows the distribution of the study population
by vascular stage. Only 2 % of the study cohort was in
stage 1 (no evidence of microvascular comorbidity and
macrovascular risk factors). Most participants (61 %)
presented in stage 2 (screen detected microvascular
complications or with risk factors for macrovascular dis-
ease), 22 % of participants were in stage 3 and 15 % in
stage 4 (end-stage micro and macro vascular complica-
tions). As found in other studies, in-patient hospital cost
[16] and mortality [17] increased with each increase in
vascular disease severity, meeting out test for construct
validity. Figure 2 shows the mean monthly in-patient
hospital cost for each stage, reported in Australian
2004–05 dollars. The mean monthly in-patient hospital
cost (±SEM) for stage 2 was, $177 ± $31, over twice that
of stage 1, $77 ± $51; stage 3 ($425 ± $86) was five and a
half times that of stage 1 and for persons in stage 4
($1243 ± $220) it was sixteen times that of persons in
stage 1. Figure 3 shows the percent of people who died
during the 5 year follow-up period by vascular stage.
The case fatality rate for this cohort is 12 % for the 5 year
period, with the death rate increasing monotonically by
vascular stage, (from 0 % in stage 1, 6 % in stage 2, 16 %
in stage 3 and 32 % in stage 4).Figure 1 The distribution of the study population by vascular
stage. Number of people by vascular stage after applying the
simplified vascular staging instrument using data from a cohort of
Aboriginal and Torres Strait Islander adults with type 2 diabetes who
participated in the Queensland Well Persons Health Check (25 May
1997–31 December 2000). N = 379. Vascular stage one (n = 9) is no
evidence of microvascular comorbidity and macrovascular risk
factors, stage two (n= 230) is presence of screen-detected
microvascular comorbidities or risk factors for macrovascular disease,
stage three (n = 83) is presence of moderate microvascular or
macrovascular comorbidities, stage four (n = 57) is the presence of
late-stage macrovascular or microvascular comorbidities.Discussion
The simplified vascular staging instrument produced a
single diabetes severity score which has shown to predict
hospitalisation and mortality and can be applied using
only data collected routinely in health practice settings
including hospital admissions. It has good construct val-
idity shown by a positive association between diseaseFigure 3 Percent of persons deceased by vascular stage.
Percent of people deceased by vascular stage after applying the
simplified vascular staging instrument using data from a cohort of
adults with type 2 diabetes who participated in the Queensland
Well Persons Health Check (25 May 1997–31 December 2000) and
registered deaths data from Queensland government births, deaths
and marriages registry (2000–05). N = 379. No deaths were registered
during the period 2000–2005 for participants assigned to vascular
stage 1. In total 12 % of the study cohort became deceased
subsequent to their health check to 31 December 2005.
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tality (Figures 2, 3). The distribution of disease severity
reflects a common observation in clinical services that
the majority of people when diagnosed with diabetes are
already in stage 2, having already accumulated a degree
of vascular damage (Figure 1).
It is unknown if this instrument would have good con-
struct validity when applied to data of other population
groups. The sample size is small, the cohort is young
and Indigenous Australians have a lipid profile which
differs from that of non-Indigenous Australians [9].
However given the structure of the instrument, there is
no reason to presume it will not prove useful in other
populations.
A strength of the instrument is its use of routinely col-
lected data from robust sources. Complex testing is not
necessary to estimate vascular stage, which can be costly
and physically invasive, repetitive and time consuming
for participants. Annual and condition specific health
checks are becoming core business of primary health
care services and hospital separation data is routinely
collected in many countries, which can be linked to
other population data. The feasibility of this type of re-
search will be enhanced with the adoption of electronic
data linkage, which is becoming more common, follow-
ing its success in Sweden [18], Western Australia [19]
and Canada [20]. With future increased availability of
linked primary health care and hospital datasets, this in-
strument could be used more widely and at low cost.
A benefit of a staged disease severity approach is its abil-
ity to assign disease severity according to clinical vascular
changes, rather than relying on date of diagnosis. Compel-
ling evidence suggests that vascular changes begin to
occur years prior to diabetes diagnosis [21]. Harris et al.,
1992 [21] studied two groups of patients with diabetes, in
the United States and Australia, and found that on-set of
diabetic retinopathy was likely to have occurred 4–7 years
before clinical diagnosis of diabetes. Furthermore other
data in their study suggested that on-set of diabetes may
in fact occur 9–12 years before clinical diagnosis. The
staged disease severity approach based on clinical markers
could capture vascular changes that may occur prior to
diagnosis and potentially adjusts for the effect of lifestyle
changes and medical and pharmacological advances in
diabetes management that may prevent or slow diabetes-
related vascular disease progression. In this respect a vas-
cular staging instrument may be more sensitive than dia-
betes duration as a proxy for health status.
Comparing the performance of the NSW instrument
and the simplified version was not feasible, given the
more extensive data requirements of the more complex
NSW instrument. Two existing severity indexes that use
administrative data were found, one did not include the
use of screen-detected micro/macrovascular risks[22],and both when applied derived severity scores within
complication categories [22,23]; this was considerably
more complex than we required. Professionals in collab-
oration [22] developed a diabetes complication severity
index (DCSI) consisting of a 13 point scale with 7 com-
plication categories. Rosenzweig and colleagues [23]
index produces 6 separate scores each with 4 levels of
severity. Both indexes discussed [22,23] were developed
to assist health organizations identify care intensity to
provide targeted interventions based on diabetes disease
stage, which requires a more finely tuned staging instru-
ment than our purpose of adjusting for heath status as a
possible confounder.
Clinical trials have shown that well managed type 2
diabetes can slow the rate of progression of diabetes-
related vascular complications reducing the incidence of
vascular events [24,25]. However this promise is not al-
ways realised in primary care practice settings. One aim
of primary health care services is the early detection of
diabetes (and other chronic diseases) and early imple-
mentation of management to keep people in vascular se-
verity stages one (no evidence of microvascular or
macrovascular risk) or two (screen detected microvascu-
lar comorbidities or macrovascular risk factors) and pre-
vent progression to more severe stages (irreversible
vascular impairment). A clear association between the
degree of vascular severity, hospital cost [26] and mor-
tality [17] is established in the literature. Therefore the
returns of slowing or preventing diabetes related vascu-
lar disease progression should reduce diabetes-related
hospital costs and mortality, and enhance the quality of
life of patients and their families.
The practical application of this instrument could be
within population health research groups and health
care delivery settings. At a population level the instru-
ment may be used to inform health services planning for
instance by identifying the distribution of vascular sever-
ity within a population group at a given point in time.
Knowing the percent of people in each disease severity
stage may help inform targeted planning of service
requirements. In addition, applying the instrument re-
peatedly over time could allow the rate of diabetes-
related vascular disease progression to be calculated and
compared over time and across groups. With the inclu-
sion of hospital separations the instrument could also be
used to monitor how well a primary care program is per-
forming in managing diabetes.
We propose to use the diabetes vascular severity sta-
ging instrument to derive a single severity score which
will be used in statistical analysis as a proxy for health
status of Indigenous Australian adults with type 2 dia-
betes. Validating the instrument in future research and
testing its generalisability with similar and diverse popu-
lation groups would be desirable.
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Many population groups are experiencing an increase in
type 2 diabetes incidence and prevalence. This instru-
ment discriminates between levels of diabetes-related
vascular disease severity, displays good construct validity
by predicting increased hospital cost and mortality with
worsening severity and can be populated with routinely
collected data. It may assist with future health service re-
search, particularly in its current form, when working
with small Australian Aboriginal and Torres Strait Is-
lander cohorts. Its use could be extended to practice set-
tings for health care planning for diabetes management
programs and monitoring vascular disease progression.
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